Clinical Efficacy Of Danshenhonghuafang In Treating Coronary Heart Disease With Stable Angina Pectoris And Blood Stasis Syndrome And Its Regulation Of Hippo Pathway

Objective: To explore the clinical effect of Danshen Honghua formula in the treatment of blood stasis and qi stagnation syndrome of stable angina pectoris of coronary heart disease,and the distribution of Sal B-Hys A in the effective group to inhibit the process of arteriosclerosis by regulating the Hippo pathway,so as to reveal the protective mechanism of Danshen Honghua formula for arteriosclerosis.Methods: 1.Clinical study: 64 patients with stable angina pectoris of coronary heart disease were randomly divided into treatment group and control group.The treatment group was given Danshen Honghua Fang + rosuvastatin(nitroglycerin),and the control group was given rosuvastatin(nitroglycerin).The treatment period was 4 weeks.The improvement of TCM Syndrome and angina score,the condition of ECG improvement were observed before and after treatment.In order to evaluate its clinical efficacy and safety,blood routine test,liver and kidney function,etc.2.Experimental study: in the model group,9 weeks after modeling,oil red staining showed that the number of carotid plaques increased significantly,and the expression gene and protein of YAP / TAZ-JNK,TNF-α in Hippo pathway increased significantly.In the treatment group,8 weeks after Sal B-Hys A treatment,oil red staining showed that the number of carotid plaques was less than that in the model group,and the expression of YAP / TAZ-JNK,TNF-α gene and protein decreased significantly compared with the model group.Results: 1.Clinical study: the treatment group and the control group had the same improvement in angina score and ECG,but there was no significant improvement in blood routine and liver and kidney function.2.Experimental study: in the model group,9weeks after modeling,oil red staining showed that the number of carotid plaques increased significantly,and the gene and protein expression of YAP/ TAZ-JNK,TNF-αin Hippo pathway increased significantly.In the treatment group,8 weeks after Sal B-Hys A treatment,oil red staining showed that the number of carotid plaques was less than that in the model group,and the gene and protein expression of YAP/TAZ-JNK,TNF-α decreased significantly compared with the model group.Conclusion: Danshen Honghua prescription can improve the clinical symptoms of patients with stable angina pectoris of coronary heart disease to a certain extent,and its mechanism may be related to its involvement in regulating the key protein YAP/TAZ-JNK of Hippo pathway,reducing the inflammatory factor TNF-α,and inhibiting the process of atherosclerosis.